Keith Loria

Many people ignored heart disease signs and symptoms during the COVID-19 pandemic — sometimes with grave consequences.

Rahul Sharma, M.S., CEO of HSBlox, say that early in his career he learned “to be the bridge between business teams and technical teams."

After having thrived in a fee-for-service healthcare system, can chronic disease specialists be enticed to switch?

Koleen Cavanaugh, vice president of marketing at Independence Blue Cross in Philadelphia, says starting in customer service was the best thing for her career.

The latest technology is changing treatments for patients.

A small fraction of those who were eligible under previous U.S. Preventive Services Task Force recommendations were screened with low-dose CT scans. New recommendations will make an additional 6.4 million Americans eligible, but a number of barriers to screening remain.

Breaches in online vaccination schedulers are the among the security problems the healthcare sector is scrambling to fix.

Corticosteroids are a mainstay but the introduction of biologics has transformed the management of this severe form of asthma.

The FDA approved proton beam radiation in 1988. But whether it is an improvement over conventional photon radiation as a treatment for many cancers remains an open question.

Devices take some of the pressure off a healthcare system coping with COVID-19.

Healthcare has successfully pivoted and collaborated. But COVID-19 also has spotlighted flaws in how hospitals are financed and the weakness of the public health infrastructure.

Eric Whitaker, M.D., credits influences in high school and medical school with his success. Now he wants to turn his new Medicare Advantage plan, Zing Health, into a training ground for Black and Latino health insurance executives — and has his sights set on unicorn status.

Last year a lull in provider mergers and acquisitions was followed by an uptick. Experts say the disruptive effect of COVID-19 may mean plenty of deals this year.

Bolstering the ACA and addressing healthcare inequities perhaps through Medicaid waivers may top the agenda. Experts see a continuation of support of ACOs and growth in enrollment in Medicare Advantage plans.

Prostate cancer is often “indolent,” so it can be monitored and not treated right away.

Results of APOLLO and REACH3 trials are scheduled for presentation at the American Society of Hematology meeting next month are expected to garner attention.

The second of a two-part story on 10 takeaways about the telehealth boom. The COVID-19 pandemic has been a bumpy ride in the U.S., featuring one controversy after another. One of the few areas of agreement is that the widespread adoption of telehealth amid the pandemic has been, by and large, a positive development.

The first of a two-part story on 10 takeaways about the telehealth boom. The COVID-19 pandemic has been a bumpy ride in the U.S., featuring one controversy after another. One of the few areas of agreement is that the widespread adoption of telehealth amid the pandemic has been, by and large, a positive development.

Therapies that target lung cancer at the molecular level are proliferating — and so are the biomarkers for guiding their use.

McKesson VP says implementing patient-centeredness involves 13 different types of professionals.

The work of moving away from fee for service is in progress. The results so far? Mixed.

Negative results for semorinemab have deflated some of the hopes for a tau as a target, although a winning strategy Alzheimer's may involve hitting several targets at once, including tau.

COVID-19 is certainly important. But oncologists, people with cancer, and complex ecosystem of cancer care in the U.S. are grappling with other important issues such as reimbursement, distorted incentives, the implications of the massive amount of data that is available, and, of course, high costs and prices. Included are thoughts from five experts on these challenges and how they might be met.

A look at how technology is making a difference in the delivery of care during the pandemic.

SGLT2 inhibitors, GLP-1 receptor agonists also tackle cardiovascular disease, renal failure.

Biosimilars to Avastin and Herceptin are catching on.

Potential agents to battle inflammation and other processes move through development pipeline.

Pacific Research Institute’s Winegarden Sees Dose of Competition as Way to Lower OOP Costs

Cardinal Health recently conducted a survey of more than 100 rheumatologists asking their feelings about biosimilars, and the findings revealed that the majority of them were familiar with and comfortable prescribing biosimilars. 

The veteran healthcare executive says this may be a Netflix vs. Blockbuster moment for hospitals. And health plans may be under pressure to meet the statutory levels for medical spending and recontract with their networks to offer enhanced payments in return for clinical improvement activities.